ERCC2 and ovarian cancer: Vella et al19has suggested that low ERCC2 expression is associated with increased chemotherapeutic sensitivity and thus considered a predictive marker for patients with ovarian cancer receiving combination of gemcitabine and cisplatin chemotherapy.